Compare CRWS & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRWS | ALGS |
|---|---|---|
| Founded | 1957 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.4M | 34.6M |
| IPO Year | 1994 | 2020 |
| Metric | CRWS | ALGS |
|---|---|---|
| Price | $2.49 | $5.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $39.33 |
| AVG Volume (30 Days) | ★ 93.0K | 44.9K |
| Earning Date | 02-11-2026 | 05-05-2026 |
| Dividend Yield | ★ 11.49% | N/A |
| EPS Growth | ★ 118.89 | 88.30 |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $70,270,000.00 | $2,186,000.00 |
| Revenue This Year | N/A | $32.20 |
| Revenue Next Year | N/A | $4.71 |
| P/E Ratio | $14.82 | ★ N/A |
| Revenue Growth | ★ 6.51 | N/A |
| 52 Week Low | $2.35 | $3.98 |
| 52 Week High | $3.14 | $13.69 |
| Indicator | CRWS | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 26.84 | 43.78 |
| Support Level | N/A | $4.80 |
| Resistance Level | $2.91 | $6.91 |
| Average True Range (ATR) | 0.09 | 0.42 |
| MACD | -0.02 | -0.10 |
| Stochastic Oscillator | 0.00 | 31.87 |
Crown Crafts Inc operates in the infant and toddler products segment of the consumer products industry through its wholly-owned subsidiaries. The infant and toddler products segment consists of infant and toddler bedding, bibs, soft bath products, disposable products, and accessories. The company serves a diverse range of customers including mass merchants, mid-tier retailers, juvenile specialty stores, value channel stores, grocery and drug stores, restaurants, internet accounts, wholesale clubs, and internet-based retailers. The company's brands include NoJo, Neat Solutions, Sassy, and Carousel. Its products are marketed under a variety of company-owned trademarks, under trademarks licensed from others, and as private-label goods.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.